Thousand Oaks, CA, United States of America

Lara C Czabaniuk

This inventor holds 7 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Amgen Inc., Vigil Neuroscience, Inc.. Active years: 2023-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lara C Czabaniuk. Retrieved from https://idiyas.com/inventor/lara-c-czabaniuk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 10.9

ph-index = 3

Forward Citations = 12(Granted Patents)

Company Filing History:

Vigil Neuroscience, Inc.

patents

where one patent can have more than one assignee

Years Active: 2023-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428425 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-09-30),

2. 12319691 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-06-03),

3. 12252489 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-03-18),

4. 11912711 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2024-02-27),

5. 11884675 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2024-01-30),

6. 11718617 - Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use (2023-08-08),

7. 11608344 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2023-03-21),

Title: Lara C Czabaniuk: Innovator in Neurodegenerative Disorder Treatments

Introduction

Lara C Czabaniuk is a prominent inventor based in Thousand Oaks, CA (US). She has made significant contributions to the field of neurodegenerative disorders through her innovative research and development of pharmaceutical compounds. With a total of 7 patents to her name, her work is paving the way for new treatment options.

Latest Patents

Czabaniuk's latest patents focus on heterocyclic compounds that act as agonists for the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). These compounds are crucial for the activation of TREM2, which plays a significant role in the treatment of neurodegenerative disorders. The disclosures provide not only the compounds themselves but also pharmaceutical compositions and methods of use, highlighting their potential in therapeutic applications.

Career Highlights

Throughout her career, Lara has worked with notable companies such as Amgen Inc. and Vigil Neuroscience, Inc. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Czabaniuk has collaborated with talented individuals, including Timothy Hopper and Jonathan B Houze. These partnerships have enhanced her research and expanded the impact of her innovations.

Conclusion

Lara C Czabaniuk is a trailblazer in the field of neurodegenerative disorder treatments, with her innovative patents and collaborations driving advancements in pharmaceutical research. Her contributions are vital for the future of medical science.

Profile summary based on public USPTO records.